Lexicon raises cash, awaits diabetes partner
This article was originally published in Scrip
Executive Summary
The Texan drug developer Lexicon Pharmaceuticals has priced a public offering in which it will raise $37.2 million net, rising to $42.7 million if underwriters exercise their over-allotment option in full. The deal will close on 23 October.